Cancer metastasis is a multistep process that requires cancer cells to leave the primary site, survive in the blood stream, and finally colonize at a distant organ. It is the major cause of cancer morbidity and mortality. The organ-specific colonization requires close interaction and communication between cancer cells and host organs. Noncoding RNAs represent the majority of the transcriptome, with long noncoding RNAs (lncRNAs) making up a significant proportion. It has been suggested that lncRNAs play a key role in all stages of tumorigenesis and metastasis. This review will provide an overview of how lncRNAs are involved in cancer cell colonization in specific organ sites and the underlying mechanisms as well as therapeutic strategies.
| LncRNAs AS NOVEL PLAYERS IN CANCER METASTASIS
Long noncoding RNAs (lncRNAs) are generally defined as RNA transcripts longer than 200 nucleotides in length, with no protein-coding potential. Through the development of high-throughput technologies such as next-generation sequencing, followed by the subsequent interrogation of lncRNAs, the potential function of lncRNAs in disease pathogenesis has gradually been recognized by researchers. LncRNAs are found in both the cytosol and the nucleus. Depending on its location, a lncRNA can regulate gene expression either in trans or in cis. [1] [2] [3] [4] The dysregulation of lncRNAs has been increasingly linked to human cancer progression. 5 Many lncRNAs are expressed at a low level with considerably high tissue or cell-type specificity, which makes them potential targets for cancer treatment. Metastasis is the most common cause of cancer death. Current evidence indicates that lncRNAs play a pivotal role in the metastatic cascade through multiple mechanisms (Table 1) .
Organ-specific metastasis is a nonrandom process and is dependent on intricate interactions between cancer cells and host organs. 6 Each organ has its unique environment, which places diverse challenges for cancer cells to colonize. Some cancers predominately spread to one organ, such as uveal melanoma metastasis to the liver or prostate cancer metastasis to bone, whereas some cancers can colonize multiple organs, such as with breast cancer metastasis to bone, lungs, brain, and liver and lung cancer metastasis to the adrenal glands, liver, brain, and bone. 7 Beyond lymph node spread, the liver, lungs, bone, and brain are the major organs colonized by different types of cancer. 7 Here, we summarize lncRNAs' role in determining the organ tropism of metastasis.
| LncRNAs in liver metastasis
The liver is the main site of distant metastasis and a major cause of death in gastrointestinal cancers such as colorectal cancer (CRC), pancreatic cancer, and tumors of the gallbladder, as well as breast cancer, sarcoma, and melanoma. Several groups [8] [9] [10] compared the expression profile of lncRNAs between CRC patients with and without liver metastasis. Thousands of differentially expressed lncRNAs were identified as related to CRC liver metastasis, suggesting that aberrantly expressed lncRNAs may play an essential role in the metastasis of CRC and could be used as novel prognostic biomarkers for liver metastasis. A novel gene transcript, colon cancer-associated transcript 2 (CCAT2) was recently cloned and found to be highly expressed in CRC. 11 Enhanced expression of CCAT2 resulted in a higher incidence of liver metastasis. 
| LncRNAs in lung metastasis
As the second most common site for metastasis colonization, almost any type of cancer has the ability to metastasize to the lungs. 
| LncRNAs in bone metastasis
Bone is the third most frequent site of metastasis, behind liver and lung.
About 60%-85% of patients with metastatic breast and prostate cancer harbor bone metastasis. 29 Cancer is generally incurable once it has spread to bones. Currently, most lncRNAs related studies focus on osteosarcoma, which is the most common primary malignant bone tumor.
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| LncRNAs in brain metastasis

| MOLECULAR MECHANISM OF LncRNAs IN CANCER METASTASIS
The metastatic cascade is a coordinated sequence of cell-biological events, which includes local cell invasion that enables cancer cells to escape from the primary site, develop new blood vessels (angiogenesis), migrate and invade through microenvironments, conduct intravasation and extravasation of blood and lymphatic vessels, survive in circulation, and finally colonize distant organs. 40 Increasing evidence has revealed the essential role of lncRNAs at every step of the metastasis cascade (Figure 1) . A clear understanding of how lncRNAs regulate multiple mechanisms in metastasis may lead to novel therapeutic intervention for patients with cancer.
| LncRNAs in cell invasion
To disseminate at distant organ sites, cancer cells must detach from the primary tumor using extracellular proteases to break down the extracellular matrix (ECM) and invade adjacent parenchyma. Metastasis then occurs when invasive cancer cells intrude into the blood and lymphatic vessels, travel via the blood stream, penetrate the endothelium, and finally settle at a distant organ and build a second tumor. 41 Epithelial-mesenchymal transition (EMT) is one centrally important process that enables stationary epithelia cells to gain migratory ability and invade. 42, 43 EMT is executed by activation of a series of transcription factors (EMT-TFs), mainly of the ZEB, SNAIL, and TWIST families. 44 Many groups have reported lncRNAs as master regulators of invasion. Here, we summarized the most thoroughly studied lncRNAs involved in regulating EMT-TFs to promote metastasis. Several lncRNAs, including lncRNA-ATB 21 and HOTAIR, 45 
| LncRNAs in angiogenesis
Angiogenesis, the development of new blood vessels from preexisting blood vessels, is required for advanced tumor growth and metastasis and is an essential step in the control of tumor progression. Blood vessels provide not only nutrients to support tumor growth but also a route for tumor cells to escape and disseminate to distant organs.
Anti-angiogenic therapies that target VEGF or its receptors have become a mainstay of cancer therapy. 53 LncRNA PVT1 is amplified in FIGURE 1 The role of lncRNAs in metastatic processes. Metastasis is characterized by a series of cell-biological events, and lncRNAs have been shown to play an indispensable role in every step of metastasis. To colonize distant organs, cancer cells must have the capacity to move, adapt, and survive in the new environment. Cell invasion: the acquisition of EMT features leads to increased migratory ability and invasiveness, which results in tumor cell dissemination. Lnc-ATB functions as a miRNA sponge, competitively binds to miR-200, and reduces the effect of miRNA on its targets ZEB1/2, thus promoting metastasis. Hypoxia: as a tumor outgrows the oxygen supply, it either co-opts preexisting vessels of host organs or induces angiogenesis. LINK-A facilitates the recruitment of BRK and LRRK2 to phosphorylate and stabilize HIF-1α. Stabilized HIF-1α upregulates downstream genes to promote cancer cell survival in low-oxygen conditions. Angiogenesis: in the meantime, the generation of new blood vessels to obtain adequate supply of oxygen and nutrients becomes an indispensable step in the process of cancer outgrowth. PVT1 directly binds to STAT3 in the nucleus and increases its protein stability which further activates VEGFA expression to stimulate angiogenesis. Tumor microenvironment: the communication between cancer cells and their microenvironment is also critical for sustained tumor growth in distant organs. In response to evolving environmental conditions, stromal cells such as immune cells, CAFs, and ECM components change over the process of cancer progression to provide favorable surroundings and support tumor growth. Treg cells have been found to promote tumor metastasis through suppressing innate and adaptive antitumor immunity. Lnc-EGFR regulates Treg differentiation and interferes with cytotoxic T cell function which leads to immune escape many types of cancer. 54 Other than regulating MYC stability, PVT1 is shown to increase capillary formation ability in endothelial cells. It forms complexes with STAT3 and stimulates angiogenesis via activation of the STAT3/VEGFA axis. 55 The upregulation of PVT1 in gastric cancer is positively correlated with VEGFA, and high levels of PVT1 Bladder cancer is frequently associated with regional lymph node metastasis. Lymphangiogenesis, which is the process of forming lymphatic vessels, is correlated with lymph node metastasis and metastasis-free survival in bladder cancer. 62 LncRNA BLACAT2 is identified from high-grade muscle-invasive bladder cancer. 63 Patients with high BLACAT2 have shorter overall and metastasis-free survival, emphasizing the role of lncRNAs in bladder cancer progression. Interestingly, BLACAT2 level also correlates with intratumoral and peritumoral lymphatic vessel density through epigenetic upregulation of VEGF-C levels in bladder cancer. Targeting BLACAT2, therefore, may be a potential target of bladder cancer with lymphangiogenesis and lymphatic metastasis. 63 Evidence suggests that some cancers can grow and metastasize without angiogenesis by using preexisting vessels of the host organ.
53
Vascular co-option also explains why some tumors do not respond to anti-angiogenic agents. The lungs, liver, and brain, which are vesselrich organs, have been described as common sites for hosting nonangiogenic tumors. 64 Lnc-BM-mediated breast cancer brain metastasis promotes cancer cell adherence and stretching on vascular capillaries. 37 Knockdown of Lnc-BM facilitates FasL-induced apoptosis via inhibition of ICAM1. This data suggests that lncRNAs also play important roles in promoting nonangiogenic tumor growth and metastasis. 37 
| LncRNAs in tumor microenvironment
In cancer metastasis, only a small number of cells that detach from the primary site can make it to the distant organs. Once they leave their , and ECM components (collagen, laminin, and proteoglycan complex). 65 The relationship between lncRNAs and endothelial cells will be discussed separately in the section "lncRNA in angiogenesis". 68 Lnc-EGFR is found to be highly expressed in
Tregs. 69 Enforced expression of lnc-EGFR stimulates Treg differentiation and interferes with cytotoxic T cell function and promotes hepatocellular carcinoma growth. 69 As such, reversing the polarization of TAMs or inhibition of immunosuppressive cells by regulating lncRNAs levels might have beneficial anti-metastatic effects.
CAFs are different from normal fibroblasts and are responsible for synthesis, deposition, and remodeling of the ECM in the tumor microenvironment. Once accumulated in the tumor, they can be activated by TGF-β, platelet-derived growth factor, FGF2, and secreted proteases. 70 Activated fibroblasts are also producers of cytokines, chemokines, metabolites, enzymes, and ECM. 71 Several recent studies have reported that CAFs-secreted TGF-β promotes cancer metastasis via regulation of lncRNA expression. 72, 73 CXCL14 high CAFs upregulated LINC00092, which directly binds to PFKBP2 and promotes metastasis of ovarian cancer by altering glycolysis. 74 These findings suggest that modulation of CAF-derived signals by targeting lncRNAs could serve as a novel therapeutic strategy.
| LncRNAs in hypoxia
Low oxygen tension, also called hypoxia, is a key microenvironment factor that arises as a result of oxygen supply and demand imbalance.
Tumor cells quickly exhaust their oxygen supply because of intensive proliferating and expanding. In the meantime, blood vessels in tumors are often highly abnormal, distended capillaries with leaky walls and sluggish flow 75 which result in insufficient oxygen supply. Hypoxia activates a number of complex signaling pathways, and hypoxiainducible factor (HIF) signaling is the major pathway involved. Under normoxic conditions, HIF transcription factors are degraded rapidly through proteasomal activity. 76 Hypoxia activates HIF signaling by stabilizing HIF-α subunits. Over the last few years, accumulating evidence has indicated that some lncRNAs are regulated by hypoxia. 77, 78 Our discussion here only summarizes the role of hypoxia-related lncRNAs in cancer metastasis. lncRNA-AK058003 is induced upon hypoxia treatment compared to normoxic conditions. 79 AK058003 is also found to be frequently upregulated in gastric cancer and promotes cancer migration and invasion via hypoxia/lncRNA-AK058003/ SNCG pathway. 79 88 we believe that oligonucleotide therapeutics may prove useful for cancer metastasis in the near future. (2) Small molecules: with the development of modern analytical techniques such as cryoelectron microscopy, nuclear magnetic resonance spectroscopy, small-angle X-ray scattering, and selective 2 0 -hydroxyl acylation analyzed by primer extension, 89 we can now better predict the secondary and tertiary structure of lncRNAs even at a single-nucleotide resolution. Small molecule inhibitors that disrupt RNA/protein or RNA/DNA interactions or target specific structural elements could provide exciting possibilities for modulating lncRNA levels and translate into clinical scenarios.
| CONCLUSION REMARKS AND PERSPECTIVE
Metastasis is a complex process that involves many diverse molecular The use of patient-derived xenograft models and genetically engineered mouse models will provide us with new tools to investigate lncRNAs' role in cancer metastasis before translating these developments into clinical scenarios. Unlike protein-coding genes, lncRNAs are still poorly defined and only a small fraction of lncRNAs has been fully characterized. How to clearly separate the role of coding genes from noncoding genes when manipulating genomic locus in vivo requires more rigorous investigation. 92 New experimental approaches and technologies could be an addition to the lncRNA field and also improve our understanding of lncRNAs' role in cancer metastasis.
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